The Oncology Institute

The Oncology Institute

The Oncology Institute is a community-based oncology practice that integrated vertically to assume financial risk for patient outcomes. Originally a California-centric physician network, it scaled through acquisition and de novo clinics to provide medical oncology, radiation therapy, and infusion services in lower-cost outpatient settings. Its economic model relies on value-based contracts with Medicare Advantage plans and commercial payers — the practice earns a fixed per-member per-month fee and retains savings when care is delivered below cost benchmarks. This makes the entity a direct wager on the shift from fee-for-service to capitated oncology. The company's deployment of capital has historically focused on clinic roll-ups and technology to manage care pathways for its attributed patient base. It has not historically disclosed discrete portfolio companies, fund commitments, or third-party asset management structures — its balance sheet is its clinical network. Geographically, the footprint extends from its core Southern California market into Arizona, Nevada, Florida, and Oregon. In March 2024, The Oncology Institute was taken private by a joint-venture group including McKesson Corporation and private equity firm CVC Capital Partners, each holding licensing rights to oncology practices in the Southeastern US — a transaction that converted the entity from a publicly watched micro-cap into a privately held platform (per the firm, March 2024). The take-private deal in early 2024 reshaped its ownership but preserved its core operating thesis. The McKesson-CVC consortium brought balance-sheet capacity to fund further clinic acquisitions without the quarterly reporting demands of public markets. Previously, the firm had grown its employed clinician count to approximately 70 oncologists managing a patient panel in the low tens of thousands — though no post-take-private team size has been published. Adjacent vehicles, philanthropic structures, or high-net-worth co-investor clubs have not been part of its disclosed architecture. The structural differentiator is its business model. The Oncology Institute is not a family office, venture fund, or institutional allocator — it is an operating company that acts as a risk-bearing healthcare provider. Its investment thesis is entirely internal and operational: it deploys capital to acquire clinic assets, hires physicians, and then manages the total cost of cancer care under capitated arrangements. This makes it an anomaly in any family-office or allocator database; evaluating it requires analyzing managed-care contracts and healthcare M&A rather than fund performance.